Recurrent Metastatic Esthesioneuroblastoma: First-in-human α/β PRRT With Actinium-225/Lutetium-177-DOTA-LM3 SSTR Antagonist Achieving Partial Response After Failure of Lutetium-177-DOTATOC PRRT.

Clin Nucl MedJul 17, 2026 (epub)

Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant et al.

✦ AI-curated · Sources linked

Case in brief

A 45-year-old woman with recurrent metastatic esthesioneuroblastoma, previously treated and symptomatic, received a novel peptide receptor radionuclide therapy (PRRT) using a somatostatin receptor antagonist labeled with actinium-225 and lutetium-177. Following two treatment cycles, imaging revealed intense uptake in multiple lesions, and after the second cycle, there was a documented partial response with significant clinical improvement, including pain reduction.

Diagnostic / clinical pearl

This case highlights the potential of combined alpha- and beta-emitting SSTR-antagonist PRRT in managing advanced esthesioneuroblastoma, demonstrating a partial response after prior treatment failures.

Source

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.